Aileron rises on promising new data from chemoprotective drug study

Rein Therapeutics

16/09/2021 14:08

** Drug developer's shares  ALRN.O  rise 3.5% to $1.19
premarket
    ** ALRN presents new data from its completed early-stage
trial, showing its drug candidate, ALRN-6924, reduced certain
side-effects of chemotherapy as well as need for blood
transfusions in patients with small cell lung cancer
 urn:newsml:reuters.com:*:nGNX6N1yXV
    ** Also presents early data from an ongoing study in healthy
volunteers, which determined the optimal dose of ALRN-6924 and
confirmed its mechanism of action
    ** The new data will inform the design of future clinical
studies testing ALRN-6924 in other cancers and with other types
of chemotherapy- co
    ** ALRN presented the results at the European Society of
Medical Oncology (ESMO) meeting
    ** ALRN up 10.6% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))